Zura Bio (NASDAQ:ZURA) Issues Quarterly Earnings Results

Zura Bio (NASDAQ:ZURA) released its quarterly earnings results on Tuesday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02), Yahoo Finance reports.

Zura Bio Stock Up 1.5 %

Shares of Zura Bio stock traded up $0.05 during trading on Wednesday, reaching $3.34. The company’s stock had a trading volume of 44,459 shares, compared to its average volume of 280,976. Zura Bio has a 12-month low of $2.00 and a 12-month high of $7.63. The business has a 50 day moving average price of $3.65 and a 200-day moving average price of $3.76.

Insider Activity at Zura Bio

In other Zura Bio news, Director Van Amstel Arnout Ploos purchased 80,000 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The shares were purchased at an average cost of $6.20 per share, for a total transaction of $496,000.00. Following the completion of the purchase, the director now directly owns 100,000 shares in the company, valued at $620,000. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 15.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Piper Sandler assumed coverage on Zura Bio in a report on Friday, May 3rd. They issued an “overweight” rating and a $26.00 target price on the stock. Cantor Fitzgerald assumed coverage on Zura Bio in a report on Wednesday, June 12th. They issued an “overweight” rating on the stock. Finally, Oppenheimer boosted their target price on Zura Bio from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Zura Bio has an average rating of “Buy” and an average price target of $19.75.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.